Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
619 artigos
A Lancet review spotlights how small vessel dysfunction silently worsens atherosclerotic coronary disease, reshaping diagnosis and treatment.
A feedforward ANGPT-TIE2 signaling loop amplifies PIK3CA-driven venous malformations, pointing to TIE2 inhibition as a more effective therapy than mTOR blockade.
Simon Hill's cardiovascular masterclass covers the Portfolio Diet, plaque regression, ApoB testing, and the sodium-potassium ratio with top experts.
A million-man study finds that adolescent cardiorespiratory fitness delivers net cardiovascular benefits that far outweigh any AF risk.
A muscle enzyme that declines in heart attack patients may hold the key to preserving cardiac function after MI.
A comprehensive GeneReviews update on Barth syndrome outlines diagnosis, new targeted therapy, and surveillance strategies for this rare X-linked disorder.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
Deleting GTPBP3 in endothelial cells blocks angiogenesis via mtROS overload — and a mitochondria-targeted antioxidant reverses the damage.
A 2-year clinical trial testing Juice Plus+ products against low-grade inflammation and biological aging markers in overweight seniors was terminated before completion.
Mendelian randomization links circulating inflammatory proteins to retinal microvascular changes, heart disease risk, and lifespan — establishing causal direction.
A 2025 review maps the molecular mechanisms driving cardiovascular aging—from inflammaging to ECM remodeling—and outlines emerging therapies.
A Phase 1/2 trial tests whether nicotinamide riboside can restore NAD+ balance and improve heart function in systolic HF patients.
